Stelara®
Understanding Stelara®
Stelara® (ustekinumab) is an immunosuppressant that helps reduce the effects of inflammatory chemicals in the body. Specifically, it is an interleukin-12 (IL-12) and interleukin-23 (IL-23) antagonist antibody used to treat psoriasis, Crohn’s disease, and ulcerative colitis (UC). By targeting these key cytokines, Stelara® helps lower inflammation, alleviate symptoms, and improve quality of life for patients with these conditions. It is commonly prescribed for moderate to severe cases of these autoimmune diseases.
How Stelara® Works:
- Targets IL-12 and IL-23, two key cytokines involved in inflammation.
- Reduces inflammation, helping to manage symptoms of psoriasis, Crohn’s disease, and UC.
- Provides long-lasting symptom relief with convenient dosing.
FDA Approval:
- 2009 – Approved for the treatment of plaque psoriasis
- 2013 – Approved for psoriatic arthritis
- 2016 – Approved for Crohn’s disease
- 2019 – Approved for ulcerative colitis (UC)
For more information, please visit the Stelara® patient website and speak with your healthcare provider to determine if Stelara® is the right treatment option for you.
Referral Form: |
MANUFACTURER: Janssen Biotech |
CLASS: Monoclonal Antibody (mAb)
Interleukin-12 (IL-12) and Interleukin-23 (IL-23) Inhibitor |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: Subcutaneous injection or IV infusion, or a combination of both (depending on the diagnosis). |
|
FREQUENCY: For psoriasis, every 12 weeks (after two starter doses); For UC and Crohn’s disease, every eight weeks (after an IV starter dose). |
Length of infusion: About ten minutes for subcutaneous injection; about 60 mins for IV infusion |
FOR MORE INFORMATION: |
Related drugs
